Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 57-73

  Schotte, A ^a   Janssen, P F M ^a   Gommeren, W ^a   Luyten, W H M L ^a   Van Gompel, P ^a   Lesage, A S ^a   De Loore, K ^a   Leysen, J E ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antipsychotic drugs; Autoradiography; Receptor occupancy; Risperidone

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DRUG METABOLITE; FLUSPIRILENE; HALOPEMIDE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; IDAZOXAN; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PALIPERIDONE; PIPAMPERONE; PRAZOSIN; QUETIAPINE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SERTINDOLE; SPIPERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; MALE; MAMMAL CELL; MEMBRANE BINDING; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULAR CLONING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; RECOMBINANT DNA TECHNOLOGY; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CELLS, CULTURED; CLOZAPINE; HALOPERIDOL; HUMANS; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RISPERIDONE;

EID: 0029930927     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245606     Document Type: Article

References (96)

1. Andersson JL, Marcus M, Nomikos GG, Svensson TH (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedeberg's Arch Pharmacol 349: 236-243
2. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch Pharmacol (in press)
3. Andrews G, Hall W, Goldstein G, Lapsey H, Bartels R, Silove D (1985) The economic costs of schizophrenia: implication for public policy. Arch Gen Psychiatry 42: 537-543
4. Ansoms C, De Backer-Dierick G, Verveecken JLTM (1977) Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon). Acta Psychiatr Scand 55: 116-122
5. Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62: 67-69
6. 2-adrenergic receptors. Mol Pharmacol 38: 348-356
7. Berman KF, Weinberger DR (1990) Prefrontal dopamine and defect symptoms in schizophrenia. In: Greden JF, Tandon R (eds) Negative schizophrenic symptoms: pathophysiology and clinical implications. Progress in Psychiatry Series, volume 28. American Psychiatric Press, Washington DC, London, England, pp 81-95
8. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double blind with orphenadrine and placebo. Clin Neuropharmacol 13:500-506
9. Borison RL, Pathiraya AP, Diamond BI, Meibach RC (1992) Risperidone clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 281: 213-218
10. Borison RL, Pathiraya AP, Diamond BI (1994) Clinical efficacy of sigma antagonists in schizophrenia. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 189-202
11. 125]iodosulpride. Neuroscience 20: 117-155
12. 3H-mepyramine. Eur J Pharmacol 48: 463-464
13. Chang RSL, Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83: 4923-4926
14. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108
15. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GA, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenic patients. J Clin Pharmacol 13: 25-40
16. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483
17. Crow TJ (1980) Molecular pathology of schizophrenia. BMJ 260: 66-68
18. Davies LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry 165 [suppl 25]: 18-21
19. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine and schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
20. Dawson TM, Gehlert DR, McCabe RT, Barnett A, Wamsley JK (1986) D-1 Dopamine receptors in the rat brain: a quantitative autoradiography analysis. J Neurosci 6: 2352-2365
21. 1 receptor. Biochem Biophys Res Commun 197: 1601-1608
22. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57: 1-78
23. 1A receptor. J Biol Chem 264: 14848-14852
24. Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23: 206-211
25. Gillan MGC, Kosterlitz HW, Paterson SJ (1980) Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol 70: 481-490
26. Goedert M, Pittaway K, Williams BJ, Emson PC (1984) Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res 304: 71-81
27. 3H-PAT. Nature 305: 140-142
28. Greenberg DA, U'Prichard DC, Snyder SH (1976) Alpha-noradrenergic receptor binding in mammalian brain: differential labelling of agonist and antagonist states. Life Sci 19: 69-76
29. Grenhoff J, Tung CS, Ugedo L, Svensson TH (1990) Effects of amperozide, a putative antipsychotic drug, on rat brain dopamine neurons recorded in vivo. Pharmacol Toxicol 66 [Suppl 1]: 29-33
30. Grohmann R, Rüther E, Sassim N, Schmidt LG (1989) Adverse effects of clozapine. Psychopharmacology 99: S101-S104
31. Häfner H (1993) What is schizophrenia? Neurol Psychiatr Brain Res 2: 36-52
32. 2 agonists to human platelets. Brit J Pharmacol 91: 223-227
33. Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47: 1609-1615
34. 3 recognition sites by radioligand binding in NG 108-15 neuroblastoma-glioma cells. Eur J Pharmacol 143:291-292
35. Hwang SB, Lam MH (1986) Species difference in the specific receptors of platelet activating factor. Biochem Pharmacol 35: 4511-4518
36. Ingvar DH (1987) Evidence for frontal/prefontal cortical dysfunction in chronic schizophrenia: the phenomenon of hypofrontality reconsidered. In: Helmchen H, Henn FA (eds) Biological perspectives of schizophrenia. Wiley New York, pp 201-211
37. 2 antagonistic properties. J Pharmacol Exp Ther 244: 685-693
38. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-796
39. 3H]prazosin. Biochem Biophys Res Commun 90: 142-149
40. 3H]-dexetimide to brain muscarinic receptor. J Neurochem 32: 421-427
41. 1 antagonist, astemizole. Mol Pharmacol 21: 294-300
42. 3H]U-69593; a highly selective ligand for the opioid κ receptor. Fur J Pharmacol 109: 281-284
43. 3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc Natl Acad Sci USA 81:4983-4987
44. 3H]hydroxy-N,N-di-n-propyl-2-amino-tetralin: Proc Natl Acad Sci USA 89: 8155-8159
45. Leysen JE, Gommeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptors. Biochem Pharmacol 27: 307-316
46. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21: 301-304
47. 3H]Sufentanil, a superior ligand for μ-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol 87: 209-225
48. 2-adrenergic receptors expressed in E. coli. Arch Int Physiol Biochim 98: P51
49. Leysen JE, Janssen PFM, Gommeren W, Wynants J, Pauwels PP, Janssen PAJ (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494-508
50. Leysen JE, Schotte A, Janssen PFM, Gommeren W, Van Gompel P, Lesage AS, De Backer MD, Luyten WHML, Amlaiky N, Megens AAHP (1995) Interaction of new antipsychotics with neurotransmitter receptors in vitro and in vivo: pharmacological to therapeutic evidence. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia, an integrated view. Alfred Benson Symposium 38, Munskgaard, Copenhagen, pp 344-360
51. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36: 518-524
52. Maj T, Mogilnicka E, Przewlocka B (1975) Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav 3: 25-27
53. Megens AAHP, Niemegeers CJE, Awouters FHL (1992) Behavioral disinhibition and depression of amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J Pharmacol Exp Ther 260: 160-167
54. 3H]imipramine to human platelet membranes. Eur J Pharmacol 96: 303-309
55. i values. J Pharmacol Exp Ther 251: 238-246
56. 2 receptors, a promising tracer for γ-emission tomography. J Labelled Compounds 34: 795-806
57. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760
58. Mong S, Wu HL, Scott MO, Lewis MA, Clark MA, Weichman BM, Kinzig ChM, Gleason JG, Crooke ST (1985) Molecular heterogeneity of leukotriene receptors: correlation of smooth muscle contraction and radioligand binding in guinea-pig lung. J Pharmacol Ther 234: 316-325
59. 3H]nitrendipine. Eur J Pharmacol 77: 201-202
60. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in rat medial prefrontal cortex. Psychopharmacology 115: 147-156
61. Oestreicher EG, Pinto GF (1987) A microcomputer program for fitting enzyme inhibition rat equations. Comput Biol Med 17: 317-321
62. 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res 419: 65-75
63. 1 receptors in the guinea-pig cerebellum: effects of kianic acid injections studied by autoradiographic methods. Brain Res 214: 155-162
64. 3H]Batrachotoxinin A 20-α-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance. Eur J Pharmacol 124: 291-298
65. Paxinos G, Watson CH (1986) The rat brain in stereotaxic coördinates, 2nd edn. Academic Press, Sydney
66. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346: 205-230
67. Pazos A, Cortés R, Palacios JM (1985a) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346: 231-249
68. Pazos A, Hoyer D, Palacios JM (1985b) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106: 539-546
69. Plassat JL, Amlaiky N, Hen R (1993) Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol 44: 229-236
70. Rainbow TC, Bleisch WV, Biegon A, McEwen BS (1982) Quantitative densitometry of neurotransmitter receptors. J Neurosci Methods 5: 127-138
71. Ramm P (1994) Advanced image analysis systems in cell, molecular and neurobiology applications. J Neurosci Methods 54: 131-149
72. 2 receptor blocker. Drug Dev Res 8: 205-211
73. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DS (1994) Binding of atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410
74. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253: 1162-1170
75. 3H]neurotensin binding site in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 333: 400-405
76. 125I]7-amino-8-iodo-ketanserin. Eur J Pharmacol [Mol Pharmacol Sec] 172: 99-106
77. 3 receptors in vivo. Eur J Pharmacol [Mol Pharmacol Sec] 218: 373-375
78. Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631: 191-202
79. 3H]SCH23390 has the characteristics of a dopamine receptor ligand in the rat central nervous system. Eur J Pharmacol 106: 211-212
80. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229-313
81. 4. Neuropsychopharmacology 7: 261-284
82. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
83. 4 receptors elevated in schizophrenia. Nature 365: 441-445
84. Snider RM, Constantine JW, Lowe III JA, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, Hess H-J (1991) A potent nonpeptide antagonist of the substance P(NK1) receptor. Science 251: 435-439
85. 3) as a target for neuroleptics. Nature 347: 146-150
86. 3H]flunitrazepam. Life Sci 22: 859-866
87. Stevens JR (1973) An anatomy of schizophrenia? Arch Gen Psychiatry 29: 177-189
88. 3H]5-hydroxytryptamine binding sites in rat brain. Mol Pharmacol 34:527-536
89. Svensson TH, Tung CS (1989) Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 136: 135-136
90. 2 antagonism. In: Vanhoute PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (eds) Serotonin, from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht, The Netherlands, pp 263-270
91. 1-receptor antagonism. J Clin Psychopharmacol (in press)
92. 3H]Nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Therap 260: 427-436
93. 2 antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50
94. Van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160: 492-494
95. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614
96. 4 agonist. Eur J Pharmacol [Mol Pharmacol Sect] 269: R1-R2